![]() ![]() ![]() For patients who were imputed as dead by 6 months, EQ-5D-5L was set to 0 and they did not contribute to the analysis of EQ-5D-5L in survivors. ![]() ![]() For patients who were known or imputed to be alive at 6 months, a value of EQ-5D-5L is multiply imputed from the continuous component of the 2-part/mixture model. For patients who were censored before 6 months, first 6-month mortality outcomes are multiply imputed from the piecewise exponential component of the bayesian 2-part/mixture model. The hazard ratio for the therapeutic anticoagulation/antiplatelet interaction is 1.39 (95% CrI, 0.87-2.19).ĪResults for the EQ visual analog scale and the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 are available in eTables 17-19 in Supplement 2.īThe probability of superiority and adjusted mean difference are computed from the posterior distribution of a bayesian 2-part/mixture model that multiply imputes 5-level EuroQol-5 Dimension (EQ-5D-5L) utility scores using patients’ baseline covariates for patients censored alive before 6 months and patients known to be alive at 6 months with unknown health-related quality of life. The hazard ratio for the combination effect is 1.34 (95% credible interval, 0.82-2.23) with a probability of superiority of 11.6%. This is estimated by multiplying the hazard ratio for antiplatelet, therapeutic anticoagulation and the interaction effect for antiplatelet and therapeutic anticoagulation. The combination effect provides the effect of giving both therapeutic anticoagulation and antiplatelet interventions together in combination (relative to giving control in both domains). GA total of 35 patients within the antiplatelet and anticoagulation domains were randomized to the prespecified combination of therapeutic anticoagulation and an antiplatelet agent. Probabilities may differ from those presented in the original trial reports for each domain due to changes in patient consent.įDomains are ordered based on the total number of patients enrolled in the domain from largest to smallest. The mean of the survival curves was taken across patients to summarize the mean survival for each intervention within the domain population.ĭThe probability of superiority (hazard ratio 0.83) is computed from a bayesian piecewise exponential model using the posterior distribution.ĮOrgan support–free days are a composite ordinal scale consisting of survival to hospital discharge and days free of organ support to day 21. For each patient within the domain population, separate survival curves are predicted assuming the patient received each intervention within the domain. For each domain, day 180 mortality rates are estimated for the population of patients randomized within that domain based on their baseline covariates and the estimated model parameters. The Kaplan-Meier curves include additional exposure and events from patients who were censored before day 180 or enrolled at sites that did not participate in 180-day follow-up.īHazard ratios 1 indicate worsened survival.ĬThe difference in 180-day mortality is determined from the 180-day mortality rates which are estimated from the primary analysis model. ADue to censoring, reported 180-day mortality rates are restricted to patients at sites participating in 180-day follow-up with known 180-day vital status. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |